| bintrafusp alfa (M7824) / EMD Serono |
2020-005703-39: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Bintrafusp alfa et doxorubicine chez les patients traités pour un sarcome avancé. |
|
|
| Not yet recruiting | 2 | 80 | Europe | Bintrafusp alfa, DOXORUBICIN, M7824, Concentrate for solution for injection/infusion, Solution for infusion, DOXORUBICIN | Institut Bergonié, Merck Healthcare KGaA | soft-tissue sarcoma sarcomes des tissus mous, soft-tissue sarcoma sarcomes des tissus mous, Diseases [C] - Cancer [C04] | | | | |
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II. |
|
|
| Not yet recruiting | 2 | 66 | Europe | Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide) | Institut Bergonié, Incyte Biosciences International Sarl | retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04] | | | | |
TRUST, NCT04874311: Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma |
|
|
| Recruiting | 2 | 80 | Europe | Bintrafusp alfa, Doxorubicin | Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma | 09/24 | 03/25 | | |
NCT04648826: Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies |
|
|
| Withdrawn | 1/2 | 0 | US | AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine | National Cancer Institute (NCI) | Sarcomas, Melanomas, Germ Cell Tumors, Epithelial Malignancies (Excluding Lung and Renal Cell Carcinomas), Pulmonary Metastases | 12/21 | 12/21 | | |
NCT04303117: NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma |
|
|
| Recruiting | 1/2 | 64 | US | NHS-IL12, M7824 | National Cancer Institute (NCI) | Kaposi Sarcoma | 09/25 | 12/28 | | |
